Bradley S Guidry1, Katherine A Kelly1, Aaron M Yengo-Kahn2, Matthews Lan1, Alan R Tang1, Silky Chotai2, Peter Morone2, Patrick D Kelly3. 1. Vanderbilt University School of Medicine, Nashville, Tennessee, USA. 2. Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 3. Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Electronic address: patrick.kelly@vumc.org.
Abstract
BACKGROUND: By stabilizing immature leaky vessel formation in neomembranes, statin drugs have been suggested as a nonsurgical treatment option for chronic subdural hematomas (cSDH). Statin therapy seems to reduce conservatively managed cSDH volume. However, the usefulness of these medications in supplementing surgical treatment is unknown. OBJECTIVE: To investigate the effect of concurrent statin therapy on outcomes after surgical treatment of cSDH. METHODS: A retrospective single-institution cohort study of surgically managed patients with convexity cSDH between 2009 and 2019 was conducted. Patients receiving this diagnosis who underwent surgical decompression were included, and those without follow-up scans were excluded. Demographic, clinical, and radiographic variables were collected. cSDH size was defined as maximum radial thickness in millimeters on axial computed tomography of the head. Multivariable linear regression was performed to identify factors (including statin use) that were associated with preoperative to follow-up cSDH size change. RESULTS: Overall, 111 patients, including 36 patients taking statins on admission, were evaluated. Median time to follow-up postoperative imaging was 30 days (interquartile range, 17-42 days). Patients on statins were older (median, 75 years, range, 68-78.25 years vs. 69 years, range, 59-7 years; P = 0.006) and reported more antiplatelet use (67% vs. 28%; P < 0.001). Median change in follow-up size was 13 mm in both statin and nonstatin groups. Adjusting for other clinical covariates, statin use was associated with greater reduction in cSDH size (CE = -6.72 mm, 95% confidence interval, -13.18 to -0.26 mm; P = 0.042). CONCLUSIONS: Statin use is associated with improved cSDH size postoperatively. Statin drugs might represent a low-cost and low-risk supplement to the surgical management for patients with cSDH.
BACKGROUND: By stabilizing immature leaky vessel formation in neomembranes, statin drugs have been suggested as a nonsurgical treatment option for chronic subdural hematomas (cSDH). Statin therapy seems to reduce conservatively managed cSDH volume. However, the usefulness of these medications in supplementing surgical treatment is unknown. OBJECTIVE: To investigate the effect of concurrent statin therapy on outcomes after surgical treatment of cSDH. METHODS: A retrospective single-institution cohort study of surgically managed patients with convexity cSDH between 2009 and 2019 was conducted. Patients receiving this diagnosis who underwent surgical decompression were included, and those without follow-up scans were excluded. Demographic, clinical, and radiographic variables were collected. cSDH size was defined as maximum radial thickness in millimeters on axial computed tomography of the head. Multivariable linear regression was performed to identify factors (including statin use) that were associated with preoperative to follow-up cSDH size change. RESULTS: Overall, 111 patients, including 36 patients taking statins on admission, were evaluated. Median time to follow-up postoperative imaging was 30 days (interquartile range, 17-42 days). Patients on statins were older (median, 75 years, range, 68-78.25 years vs. 69 years, range, 59-7 years; P = 0.006) and reported more antiplatelet use (67% vs. 28%; P < 0.001). Median change in follow-up size was 13 mm in both statin and nonstatin groups. Adjusting for other clinical covariates, statin use was associated with greater reduction in cSDH size (CE = -6.72 mm, 95% confidence interval, -13.18 to -0.26 mm; P = 0.042). CONCLUSIONS: Statin use is associated with improved cSDH size postoperatively. Statin drugs might represent a low-cost and low-risk supplement to the surgical management for patients with cSDH.
Authors: Michelle C Odden; Mark J Pletcher; Pamela G Coxson; Divya Thekkethala; David Guzman; David Heller; Lee Goldman; Kirsten Bibbins-Domingo Journal: Ann Intern Med Date: 2015-04-21 Impact factor: 25.391
Authors: Joseph A Salami; Haider Warraich; Javier Valero-Elizondo; Erica S Spatz; Nihar R Desai; Jamal S Rana; Salim S Virani; Ron Blankstein; Amit Khera; Michael J Blaha; Roger S Blumenthal; Donald Lloyd-Jones; Khurram Nasir Journal: JAMA Cardiol Date: 2017-01-01 Impact factor: 14.676
Authors: Hishaam Ismael; Mathilda Horst; Maria Farooq; Jack Jordon; Joe H Patton; Ilan S Rubinfeld Journal: Am J Surg Date: 2011-03 Impact factor: 2.565
Authors: Andrea Di Cristofori; Paolo Remida; Mirko Patassini; Lorenzo Piergallini; Raffaella Buonanno; Raffaele Bruno; Giorgio Carrabba; Giacomo Pavesi; Corrado Iaccarino; Carlo Giorgio Giussani Journal: Surg Neurol Int Date: 2022-03-18